Dr. Asma Patel, VP of Integrated Development Services, and Matt Paterson, Chief Strategy Officer and Head of Translational Pharmaceutics® platform, recently contributed to Drug Development & Delivery's special feature, 'Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient & Secure'.
When speaking on our Translational Pharmaceutics® platform, Paterson says it is a disruptive approach to drug development that integrates drug product formulation and manufacturing with clinical testing, setting us apart from other industry providers. He says, “The integration of services improves decision-making while reducing time and white space, so milestones can be achieved as efficiently as possible, shortening drug development timelines as a whole.”
Dr. Patel discusses how the platform addressed a product development challenge for one client. She explains, “We worked on a project for Rigel Pharmaceuticals, which was developing R552, a small molecule RIPK1 inhibitor for autoimmune and inflammatory disorders. Preclinical data showed potential solubility issues and, therefore, the client wanted to evaluate a range of formulations for the first-in-human (FIH) study. Leveraging the Translational Pharmaceutics® platform, we conducted an adaptive FIH study to develop lipid and solid dispersion (SDD) formulations to enhance solubility. These formulations underwent rapid, iterative testing, allowing for immediate adjustments and optimization.”
Read the full article here on Drug Development & Delivery's website.